Search
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age.
Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, PlainPemoline
go.drugbank.com/drugs/DB01230ApprovedIllicitWithdrawnIn 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons.
Categories: Psychostimulants, Agents Used for ADHD and NootropicsTrimethadione
go.drugbank.com/drugs/DB00347ApprovedWithdrawnAn anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnwith [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigational[A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).
Imdevimab
go.drugbank.com/drugs/DB15940ApprovedInvestigationalImdevimab is a monoclonal antibody combined with [casirivimab] in Regeneron's antibody cocktail known as REGEN-COV2 for the treatment of COVID-19. … They are reserved for Emergency Use Authorization (EUA) only.[L23524] In November 2021, the same indication was approved by the EMA.
Categories: Antiinfectives for Systemic Use, Approved Treatments for COVID-19Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled
Phylloquinone
go.drugbank.com/drugs/DB01022ApprovedInvestigationalVitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X. It is indicated ...
Mixtures: Vitalipid - Vitaminkonzentrat zur Infusionsbereitung für Kinder, Vitalipid - Vitaminkonzentrat zur Infusionsbereitung für ErwachseneCinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedA local anesthetic of the amide type now generally used for surface anesthesia.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Anesthetics for Topical UseApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigational[A203618] Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.